Lanean...
High Dose Erythropoietin in ELGANs does not Alter Risk of Retinopathy of Prematurity
INTRODUCTION: The Preterm Erythropoietin (Epo) Neuroprotection (PENUT) Trial sought to determine the safety and efficacy of early high-dose Epo as a potential neuroprotective treatment. We hypothesized that Epo would not increase the incidence or severity of retinopathy of prematurity (ROP). METHODS...
Gorde:
| Argitaratua izan da: | Neonatology |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7855231/ https://ncbi.nlm.nih.gov/pubmed/33113526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000511262 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|